SABCS 2022 | SERDs for patients with ER+/HER2- breast cancer
Mafalda Oliveira, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses selective estrogen receptor downregulators (SERDs) for patients with patients with ER-positive, HER2-negative breast cancer. Next-generation oral SERDs have demonstrated to be potentially superior to the standard endocrine treatment in patients that progress on prior endocrine treatment and therefore hold the potential to become the treatment backbone for this patient population. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We have now two trials, one Phase III trial, and now SERENA-2, that show us that this next-generation oral certs are potentially better than the standard endocrine treatment in patients that progress to prior endocrine treatment.
I really think that these new drugs have the potential to become the backbone of treatment of patients with the ER-positive/HER2-negative metastatic breast cancer...
We have now two trials, one Phase III trial, and now SERENA-2, that show us that this next-generation oral certs are potentially better than the standard endocrine treatment in patients that progress to prior endocrine treatment.
I really think that these new drugs have the potential to become the backbone of treatment of patients with the ER-positive/HER2-negative metastatic breast cancer. And let’s wait for the results of the trials that are ongoing in first-line and the trials that are planned also in the early setting, to see that if whether these more potent endocrine agents can substitute the current standard of care.
Read more...
